$0.05
$3.12
bear $0.05
base $2.11
bull $3.12
margin of safety $0.90
market price* $6.79
Business condition attached to the margin of safety
Confirmation, over the next one to two quarterly reports (through Q3-Q4 2026, when the 2025 Corporate Realignment Plan is scheduled to be fully phased in), that operating cash flow has moved durably into positive territory consistent with the announced $65 million-plus in annualized cost savings, rather than reflecting a single favorable half-year.
Maravai LifeSciences supplies specialty reagents used to manufacture nucleic-acid-based medicines (mRNA, oligonucleotides) and to test biologic drugs for safety, through two brands: TriLink (nucleic acid production, including the CleanCap mRNA-capping technology used widely in mRNA vaccine and therapeutic manufacturing) and Cygnus (bioanalytical safety testing reagents for biopharma manufacturers). The company went public via a SPAC merger in late 2020, at the height of COVID-19 vaccine demand, and its revenue has fallen every year since as that one-time surge unwound: from $883 million in 2022 to $186 million in 2025. Revenue tied to high-volume CleanCap sales for commercial vaccine programs fell from about a quarter of total revenue in 2024 to zero in 2025 -- that specific headwind is now fully behind the company, since it cannot fall further than zero. The two brands look very different today. Cygnus, the safety-testing business, earned roughly $66 million of revenue in 2025 at very high margins (about two-thirds of revenue converts to segment profit) and grew about 5% year over year -- a steady, recurring, funded-from-its-own-cash business. TriLink, the nucleic-acid business, generated about $120 million of revenue in 2025 but operated at a segment loss, because manufacturing capacity built for the pandemic-era volumes is now underused. In August 2025, following a leadership change, the company cut roughly a quarter of its workforce and consolidated a facility, targeting more than $65 million of annualized cost savings (raised from an initial $50 million target); most of the cash cost of this action was already paid in 2025, with about $2 million remaining. The first half of 2026 shows early, tangible evidence the plan is working: operating cash flow swung from a $20 million outflow in the first half of 2025 to a $13 million inflow in the first half of 2026, alongside 24% revenue growth, even as the CleanCap tailwind stayed at zero. We build our estimate of the company's true, sustainable owner earnings from reported operating cash flow, adding back stock-based compensation and normalized capital spending as real costs rather than treating them as free. On that basis, owner earnings were negative in each of the last three years (2023, 2024 and 2025) -- roughly $(72) million, $(59) million and $(93) million respectively -- even after the pandemic-era revenue is fully excluded. We use the median of these three post-pandemic years, rather than the two peak COVID years (2021-2022, which were worth roughly $2.02-$2.19 per share on this same basis but reflect a business that no longer exists), as the level from which we build forward. The 2021-2022 figures are recorded for reference but explicitly not used to value the company. Owner earnings got worse, not better, in the most recently completed year (2025 versus 2024), so our base case's near-term recovery is not simply optimism: it rests on the already-implemented cost cuts described above and on cash-flow evidence from the first half of 2026 that those cuts are taking hold. In our base case, Cygnus continues growing at roughly its demonstrated 5% pace (a proven, self-funded pattern, not a hoped-for acceleration), TriLink's revenue is held flat (we credit no recovery of the lost vaccine volume and no new named growth driver), and the announced cost savings are substantially, though not perfectly, realized over the following one to two years. That combination turns owner earnings modestly positive within about two years and lets it grow slowly thereafter with Cygnus. Beyond the ten-year explicit period, we assume only what Cygnus's long operating history already supports -- a stable, modestly growing testing franchise -- and give no credit for a TriLink recovery beyond what is already in the base case, since nothing in the filings supports assuming more. Our bear case assumes the cost-cutting program only partly sticks, Cygnus's growth slows under normal biopharma-spending pressure, and TriLink's excess capacity is not resolved for several years -- a slower, harder version of the same story, not a hypothetical catastrophe. Our bull case assumes the savings program is fully realized (management has already raised its own savings estimate once) and Cygnus keeps compounding at its demonstrated rate with no deceleration. The company has also written down goodwill twice in two years (about $166 million in 2024 and a further $43-85 million in 2025), tied to an underperforming enzyme-products acquisition (Alphazyme) folded into TriLink -- a pattern of overpaying for a deal and then writing it back down that we treat as a real, if already-recognized, mark against management's capital allocation, and a reason for caution in the bear case about further such write-downs, rather than crediting new value to future acquisitions. On debt: the company carries a term loan, roughly $147 million outstanding in mid-2026, at a floating rate currently around 6.9% and maturing in October 2027. It used roughly $145 million of its cash reserves in the first half of 2026 to prepay a large portion of this loan, leaving cash of about $70 million against that debt -- net debt of roughly $77 million, or about $0.30 per share, which we subtract from the value of the underlying business before arriving at a per-share figure. Because the remaining loan matures in about 18 months, refinancing risk is real if the turnaround disappoints: this is the main reason our bear case, while not deeply negative, comes out only a few cents per share once debt is subtracted -- a business under stress for several more years, with a debt maturity to clear, leaves little cushion for shareholders even though it does not appear headed for insolvency. Putting this together: the business is worth on the order of $0.05 per share in our bear case, about $2.11 per share in our base case, and about $3.12 per share in our bull case, after subtracting net debt in each. Given how much of the base and bull case depends on a cost-cutting program that has only one half-year of confirming evidence so far, and given the demonstrated history of value-destroying acquisitions and the approaching debt maturity, the margin-of-safety price is set at a substantial discount to the base-case estimate, and it assumes confirmation over another quarter or two that the cost savings are durable rather than a single good print. One item we could not fully reconcile: 2024 net income included a roughly $669 million non-cash gain from remeasuring a tax-related payment obligation tied to the company's original SPAC structure, which is unrelated to operating performance; we built our estimates from operating cash flow specifically so that this and similar large non-cash swings do not distort the picture.